ClinicalTrials.gg
CompletedNCT02395081Updated Mar 23, 2021Results posted

Trial of Vitamin D Supplements to Raise Calcidiol Levels of Pregnant Women in Mongolia

An interventional study of 600 IU Vitamin D3 in prenatal vitamin and 2000 IU Vitamin D3 in prenatal vitamin in Pregnancy and Vitamin D Deficiency, sponsored by Brigham and Women's Hospital. Completed at 1 site in Mongolia. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-23.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

A double-blind randomized, placebo-controlled trial comparing the impact of 600 IU, 2000 IU, or 4000 IU of Vitamin D3 on third trimester 25(OH)D levels and change from baseline. The Vitamin D will be integrated in a standard prenatal vitamin, which will be taken from 12-16 weeks' gestation and continue throughout pregnancy. Umbilical cord 25(OH)D levels will also be determined. The investigators will generate preliminary data regarding Vitamin D intake and hypertensive disorders, blood pressure, and arterial function measured by tonography. The investigators will independently test blood pressure and proteinuria to identify preeclampsia cases.

Read the detailed description

Vitamin D deficiency (serum 25(OH)D levels \<20 ng/ml or 50 nmol/l) is widespread among Mongolians and is nearly universal during the winter months. The investigators have conducted a series of studies which have shown nearly universal Vitamin D deficiency in the winter months.

Observational studies in the U.S. have linked low 25(OH)D levels in women to a higher risk of preeclampsia. Mongolians also report levels of preeclampsia that are 3 times higher than those in the U.S (official reports cite 15%, though this may include gestational hypertension).

Given the widespread Vitamin D deficiency in Mongolian women, the high prevalence of hypertensive pregnancy in Mongolia, and the observational studies linking low 25(OH)D levels with preeclampsia risk, the investigators are conducting a pilot Vitamin D dosing trial to:

  • Determine what level of Vitamin D supplementation is needed to secure 25(OH)D levels of at least 20 ng/ml in pregnant Mongolian women
  • Generate preliminary data in support of a funding application for a larger trial of Vitamin D supplements to prevent preeclampsia in Mongolia

A double-blind randomized, placebo-controlled trial comparing the impact of 600 IU, 2000 IU, or 4000 IU of Vitamin D3 on third trimester 25(OH)D levels and change from baseline. The Vitamin D will be integrated in a standard prenatal vitamin, which will be taken from 12-16 weeks' gestation and continue throughout pregnancy. Umbilical cord 25(OH)D levels will also be determined. The investigators will generate preliminary data regarding Vitamin D intake and hypertensive disorders, blood pressure, and arterial function measured by tonography. The investigators will independently test blood pressure and proteinuria to identify preeclampsia cases.

The investigators will enroll 360 women who plan to receive their prenatal care and deliver at Zuun Kharaa Hospital in the Selenge province in northern Mongolia. Enrollment will be stratified by season. 120 women will be randomized to each of the three doses of vitamin D (600, 2000, 4000 IU) included in a standard prenatal vitamin.

Calcemia will be monitored two months after randomization and weeks 36-40 of pregnancy. Adverse events of pregnancy will be reported to the Data Safety and Monitoring Board (DSMB) and Institutional Review Board (IRB) per protocol.

Data will be gathered by a Mongolian study coordinator and local clinicians. A DSMB comprised of a U.S. and Mongolian clinicians and statisticians will monitor study data for safety.

02

Conditions studied

  • Pregnancy
  • Vitamin D Deficiency

Keywords

  • pregnancy
  • Mongolia
  • Vitamin D
  • preeclampsia
03

In context

Vitamin D Deficiency

801 studies on the registry are indexed under Vitamin D Deficiency; 60 are open to participants now.

This study's enrollment of 360 is above the median of 78 across 590 interventional studies indexed under Vitamin D Deficiency.

Browse Vitamin D Deficiency studies →

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,267 studies on the registry; 228 are open to participants now.

Of its 116 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • 12-16 weeks pregnant
  • Receiving prenatal care at Zuun Kharaa Hospital and planning to deliver at Zuun Kharaa Hospital
  • Willing not to take any additional vitamin D supplements, other than the study dispensed pills

Exclusion criteria

Exclusion Criteria:

  • Existing known seizure disorder, renal failure, parathyroid disease, thyroid disease, sarcoidosis, cancer, or tuberculosis. (Tuberculosis is routinely screened in pregnancy)
  • History of kidney stones
  • Known sensitivity to multivitamin preparations
  • Taking vitamin D supplements containing >600 IU/day.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
360 participants (actual)

Study arms

  • Placebo comparator
    600 IU

    Women will receive prenatal vitamins containing 600 IU of Vitamin D.

    Dietary Supplement: 600 IU Vitamin D3 in prenatal vitamin

  • Experimental
    2000 IU

    Women will receive prenatal vitamins containing 2000 IU of Vitamin D.

    Dietary Supplement: 2000 IU Vitamin D3 in prenatal vitamin

  • Experimental
    4000 IU

    Women will receive prenatal vitamins containing 4000 IU of Vitamin D.

    Dietary Supplement: 4000 IU Vitamin D3 in prenatal vitamin

Interventions

  • Dietary supplement600 IU Vitamin D3 in prenatal vitamin

    Women will receive 600 IU 25(OH)D in prenatal vitamin.

  • Dietary supplement2000 IU Vitamin D3 in prenatal vitamin

    Women will receive 2000 IU 25(OH)D in prenatal vitamin.

  • Dietary supplement4000 IU Vitamin D3 in prenatal vitamin

    Women will receive 4000 IU 25(OH)D in prenatal vitamin.

06

What researchers measure

Primary outcomes

  1. Total Serum 25(OH)D Concentration

    Circulating vitamin D at the end of the study as measured by VIDAS® enzyme linked fluorescent assay (ELFA)

    Time frame: 36 weeks gestation or delivery, if delivery occurred before 36 weeks

Secondary outcomes

  1. The Number of Participants With Preeclampsia

    Preeclampsia as measured by new onset hypertension after 20 weeks gestation and proteinuria.

    Time frame: After 20 weeks gestation

  2. Average Monthly Blood Pressure

    Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were measured in mm Hg at each antenatal care visit by the Study Coordinator, using the Omron- Elite 7300 (Omron Healthcare, Bannockburn, Illinois, USA) automated blood pressure monitor. Three blood pressure readings were taken after at least five minutes seated rest. For the analysis of mean blood pressures at each antenatal visit, the three readings were averaged for each participant.

    Time frame: During pregnancy

  3. Arterial Tonometry

    Investigators will assess Augmentation Index (AIx) and Pulse Wave Velocity (PWV) by study arm, as measured by AtCor Medical SphygmoCor device. THIS TONOMETER FAILED AND COULD NOT BE REPAIRED, SO WE ARE NOT PRESENTING THESE DATA AS OUTCOMES.

    Time frame: 36 weeks gestation

  4. Number of Patients With Preterm Delivery as Measured by Clinical Diagnosis

    Gestational age was determined clinically by last menstrual period and by routine first trimester ultrasound which was universal; where these differed by more than 10 days, the ultrasound date was used. Gestational age at delivery was recorded by clinicians and rounded to the nearest week. Preterm delivery was defined as delivery before the 37th week of gestation.

    Time frame: During pregnancy

  5. Casarean Section as Measured by Medical Record Abstraction

    Cesarean section was abstracted from the labor and delivery chart.

    Time frame: Delivery

  6. Assisted Vaginal Delivery as Measured by Medical Record Abstraction

    Assisted vaginal delivery with forceps delivery was abstracted from the labor and delivery chart.

    Time frame: Delivery

  7. Number of Small for Gestational Age (SGA) Neonates as Measured by Medical Record Abstraction

    SGA defined by the lowest 10th percentiles of sex-specific birthweight for gestational age charts of the INTERGROWTH-21st study

    Time frame: Delivery

  8. Number of Large for Gestational Age (LGA) Neonates as Measured by Medical Record Abstraction

    LGA defined by the highest 10th percentiles of sex-specific birthweight for gestational age charts of the INTERGROWTH-21st study

    Time frame: Delivery

  9. Mean Calcemia as Measured by Serum Calcium Test (2mo)

    Measured on a semi-automated photometer (Humalyzer 3500, Human Diagnostics, Magdeburg, Germany)

    Time frame: 2 months after randomization

  10. Number of Patients With Proteinuria as Measured by Urine Dipstick

    Proteinuria at last antenatal visit (usually 36-40 weeks' gestation), measured by 1+ Standard Diagnostics UroColor 10 10 (Kyonggi-do, South Korea) reagent strips

    Time frame: 36-40 weeks gestation/delivery

  11. Number of Patients With Hypertensive Disorders of Pregnancy as Measured by Clinical Diagnosis

    In Mongolia, clinician-diagnosed preeclampsia may include a blood pressure increases \>30 mm Hg above early pregnancy, with or without documented hypertension, proteinuria, or symptoms such as headache and edema

    Time frame: During pregnancy

  12. Number of Patients With Bacterial Vaginosis as Measured by Potassium Hydroxide (KOH) Wet Mount

    Bacterial vaginosis was routinely screened by potassium hydroxide wet mount at the first antenatal visit, at 28 weeks' and 32 weeks' gestation. It was also diagnosed by whiff test. We included both wet mount and whiff test positive in the bacterial vaginosis endpoint

    Time frame: During pregnancy

  13. Mean Calcemia as Measured by Serum Calcium Test (36-40 Weeks)

    Measured on a semi-automated photometer (Humalyzer 3500, Human Diagnostics, Magdeburg, Germany)

    Time frame: 36-40 weeks of pregnancy/delivery

07

Results

Posted Mar 23, 2021

Participant flow

Participant flow — Overall Study
Milestone600 IU2000 IU4000 IU
Started119121120
Completed112116116
Not completed754
Withdrew: Withdrawal by subject110
Withdrew: Moved where blood couldn't be collected413
Withdrew: Fetal loss231

Outcome measures

PrimaryTotal Serum 25(OH)D Concentration

Circulating vitamin D at the end of the study as measured by VIDAS® enzyme linked fluorescent assay (ELFA)

Time frame:
36 weeks gestation or delivery, if delivery occurred before 36 weeks
Reported as:
Mean · nmol/l
Total Serum 25(OH)D Concentration
nmol/l600 IU2000 IU4000 IU
Total Serum 25(OH)D Concentration46 ± 2170 ± 2381 ± 29
SecondaryThe Number of Participants With Preeclampsia

Preeclampsia as measured by new onset hypertension after 20 weeks gestation and proteinuria.

Time frame:
After 20 weeks gestation
Reported as:
Count of participants · Participants
The Number of Participants With Preeclampsia
Participants600 IU2000 IU4000 IU
The Number of Participants With Preeclampsia100
SecondaryAverage Monthly Blood Pressure

Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were measured in mm Hg at each antenatal care visit by the Study Coordinator, using the Omron- Elite 7300 (Omron Healthcare, Bannockburn, Illinois, USA) automated blood pressure monitor. Three blood pressure readings were taken after at least five minutes seated rest. For the analysis of mean blood pressures at each antenatal visit, the three readings were averaged for each participant.

Time frame:
During pregnancy
Reported as:
Mean · mmHg
Average Monthly Blood Pressure
mmHg600 IU2000 IU4000 IU
SBP wk 16-20104.5 ± 9.2104.5 ± 8.7105.5 ± 9.7
SBP wk 20-24105.1 ± 9.0103.6 ± 8.2105.4 ± 8.9
SBP wk 24-28104.9 ± 9.1103.3 ± 8.1104.0 ± 9.3
SBP wk 28-32104.5 ± 8.7103.9 ± 9.7105.4 ± 9.3
SBP wk 36-40110.8 ± 10.1110.6 ± 9.5111.1 ± 11.0
DBP wk 16-2063.8 ± 8.763.7 ± 8.765.2 ± 9.0
DBP wk 20-2463.2 ± 9.063.1 ± 8.663.8 ± 9.6
DBP wk 24-2864.2 ± 9.862.6 ± 9.463.5 ± 9.6
DBP wk 28-3264.4 ± 8.763.6 ± 9.265.1 ± 9.2
DBP wk 32-3667.2 ± 8.866.5 ± 9.467.1 ± 9.5
DBP wk 36-4070.4 ± 9.771.0 ± 10.271.7 ± 10.6
Statistical analysis
  • 600 IU vs 2000 IU vs 4000 IU · ANOVA · p = 0.70 (SBP wk 16-20)
SecondaryArterial Tonometry

Investigators will assess Augmentation Index (AIx) and Pulse Wave Velocity (PWV) by study arm, as measured by AtCor Medical SphygmoCor device. THIS TONOMETER FAILED AND COULD NOT BE REPAIRED, SO WE ARE NOT PRESENTING THESE DATA AS OUTCOMES.

Time frame:
36 weeks gestation

Results for this outcome have not been posted.

SecondaryNumber of Patients With Preterm Delivery as Measured by Clinical Diagnosis

Gestational age was determined clinically by last menstrual period and by routine first trimester ultrasound which was universal; where these differed by more than 10 days, the ultrasound date was used. Gestational age at delivery was recorded by clinicians and rounded to the nearest week. Preterm delivery was defined as delivery before the 37th week of gestation.

Time frame:
During pregnancy
Reported as:
Count of participants · Participants
Number of Patients With Preterm Delivery as Measured by Clinical Diagnosis
Participants600 IU2000 IU4000 IU
Number of Patients With Preterm Delivery as Measured by Clinical Diagnosis985
Statistical analysis
  • 600 IU vs 2000 IU vs 4000 IU · Chi-squared · p = 0.49
SecondaryCasarean Section as Measured by Medical Record Abstraction

Cesarean section was abstracted from the labor and delivery chart.

Time frame:
Delivery
Reported as:
Count of participants · Participants
Casarean Section as Measured by Medical Record Abstraction
Participants600 IU2000 IU4000 IU
Casarean Section as Measured by Medical Record Abstraction222726
Statistical analysis
  • 600 IU vs 2000 IU vs 4000 IU · Chi-squared · p = 0.79
SecondaryAssisted Vaginal Delivery as Measured by Medical Record Abstraction

Assisted vaginal delivery with forceps delivery was abstracted from the labor and delivery chart.

Time frame:
Delivery
Reported as:
Count of participants · Participants
Assisted Vaginal Delivery as Measured by Medical Record Abstraction
Participants600 IU2000 IU4000 IU
Assisted Vaginal Delivery as Measured by Medical Record Abstraction000
SecondaryNumber of Small for Gestational Age (SGA) Neonates as Measured by Medical Record Abstraction

SGA defined by the lowest 10th percentiles of sex-specific birthweight for gestational age charts of the INTERGROWTH-21st study

Time frame:
Delivery
Reported as:
Count of participants · Participants
Number of Small for Gestational Age (SGA) Neonates as Measured by Medical Record Abstraction
Participants600 IU2000 IU4000 IU
Number of Small for Gestational Age (SGA) Neonates as Measured by Medical Record Abstraction122
Statistical analysis
  • 600 IU vs 2000 IU vs 4000 IU · Chi-squared · p = 0.83
SecondaryNumber of Large for Gestational Age (LGA) Neonates as Measured by Medical Record Abstraction

LGA defined by the highest 10th percentiles of sex-specific birthweight for gestational age charts of the INTERGROWTH-21st study

Time frame:
Delivery
Reported as:
Count of participants · Participants
Number of Large for Gestational Age (LGA) Neonates as Measured by Medical Record Abstraction
Participants600 IU2000 IU4000 IU
Number of Large for Gestational Age (LGA) Neonates as Measured by Medical Record Abstraction252633
Statistical analysis
  • 600 IU vs 2000 IU vs 4000 IU · Chi-squared · p = 0.39
SecondaryMean Calcemia as Measured by Serum Calcium Test (2mo)

Measured on a semi-automated photometer (Humalyzer 3500, Human Diagnostics, Magdeburg, Germany)

Time frame:
2 months after randomization
Reported as:
Mean · mmol/L
Mean Calcemia as Measured by Serum Calcium Test (2mo)
mmol/L600 IU2000 IU4000 IU
Mean Calcemia as Measured by Serum Calcium Test (2mo)2.2 ± 0.22.2 ± 0.22.2 ± 0.2
Statistical analysis
  • 600 IU vs 2000 IU vs 4000 IU · ANOVA · p = 0.24
SecondaryNumber of Patients With Proteinuria as Measured by Urine Dipstick

Proteinuria at last antenatal visit (usually 36-40 weeks' gestation), measured by 1+ Standard Diagnostics UroColor 10 10 (Kyonggi-do, South Korea) reagent strips

Time frame:
36-40 weeks gestation/delivery
Reported as:
Count of participants · Participants
Number of Patients With Proteinuria as Measured by Urine Dipstick
Participants600 IU2000 IU4000 IU
Number of Patients With Proteinuria as Measured by Urine Dipstick220
Statistical analysis
  • 600 IU vs 2000 IU vs 4000 IU · Chi-squared · p = 0.39
SecondaryNumber of Patients With Hypertensive Disorders of Pregnancy as Measured by Clinical Diagnosis

In Mongolia, clinician-diagnosed preeclampsia may include a blood pressure increases \>30 mm Hg above early pregnancy, with or without documented hypertension, proteinuria, or symptoms such as headache and edema

Time frame:
During pregnancy
Reported as:
Count of participants · Participants
Number of Patients With Hypertensive Disorders of Pregnancy as Measured by Clinical Diagnosis
Participants600 IU2000 IU4000 IU
Number of Patients With Hypertensive Disorders of Pregnancy as Measured by Clinical Diagnosis433
Statistical analysis
  • 600 IU vs 2000 IU vs 4000 IU · Chi-squared · p = 0.89
SecondaryNumber of Patients With Bacterial Vaginosis as Measured by Potassium Hydroxide (KOH) Wet Mount

Bacterial vaginosis was routinely screened by potassium hydroxide wet mount at the first antenatal visit, at 28 weeks' and 32 weeks' gestation. It was also diagnosed by whiff test. We included both wet mount and whiff test positive in the bacterial vaginosis endpoint

Time frame:
During pregnancy
Reported as:
Count of participants · Participants
Number of Patients With Bacterial Vaginosis as Measured by Potassium Hydroxide (KOH) Wet Mount
Participants600 IU2000 IU4000 IU
Number of Patients With Bacterial Vaginosis as Measured by Potassium Hydroxide (KOH) Wet Mount171918
Statistical analysis
  • 600 IU vs 2000 IU vs 4000 IU · Chi-squared · p = 0.95
SecondaryMean Calcemia as Measured by Serum Calcium Test (36-40 Weeks)

Measured on a semi-automated photometer (Humalyzer 3500, Human Diagnostics, Magdeburg, Germany)

Time frame:
36-40 weeks of pregnancy/delivery
Reported as:
Mean · mmol/L
Mean Calcemia as Measured by Serum Calcium Test (36-40 Weeks)
mmol/L600 IU2000 IU4000 IU
Mean Calcemia as Measured by Serum Calcium Test (36-40 Weeks)2.3 ± 0.22.3 ± 0.22.3 ± 0.2

Adverse events

Collected over From study enrollment (12-16 weeks gestation) to delivery. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
600 IU0/119 (0%)0/119 (0%)0/119 (0%)
2000 IU0/121 (0%)0/121 (0%)0/121 (0%)
4000 IU0/120 (0%)0/120 (0%)0/120 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)600 IU2000 IU4000 IUTotal
<=18 years0000
Between 18 and 65 years119121120360
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)600 IU2000 IU4000 IUTotal
Female119121120360
Male0000
08

Study locations

1 site
  • Zuun Kharaa Hospital
    Selenge, Selenge Aimag, Mongolia
09

References and documents

Publications

  • Enkhmaa D, Tanz L, Ganmaa D, Enkhtur S, Oyun-Erdene B, Stuart J, Chen G, Carr A, Seely EW, Fitzmaurice G, Buyandelger Y, Sarantsetseg B, Gantsetseg G, Rich-Edwards J. Randomized trial of three doses of vitamin D to reduce deficiency in pregnant Mongolian women. EBioMedicine. 2019 Jan;39:510-519. doi: 10.1016/j.ebiom.2018.11.060. Epub 2018 Dec 11. PubMed 30552064 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2021, 4 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2015
First posted
Mar 20, 2015
Start
Feb 2015
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Results first posted
Mar 23, 2021
Last update
Mar 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02395081
Collaborators
National Center for Maternal and Child Health Research, Mongolia, Zuun Kharaa Hospital
Responsible party
Janet Rich-Edwards (Director of Developmental Epidemiology, Brigham and Women's Hospital) — Principal investigator
First posted
Mar 20, 2015
Start date
Feb 2015
Primary completion
Dec 2016
Completion
Dec 2016
Results posted
Mar 23, 2021
Last update
Mar 23, 2021

Study contacts

Janet Rich-Edwards, ScD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion